New combinations in metastatic colorectal cancer: what are our expectations?

Oncologist. 2005 May;10(5):320-2. doi: 10.1634/theoncologist.10-5-320.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bevacizumab
  • Camptothecin / administration & dosage
  • Camptothecin / analogs & derivatives*
  • Cetuximab
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / pathology
  • Fluorouracil / administration & dosage
  • Humans
  • Irinotecan
  • Organoplatinum Compounds / administration & dosage
  • Oxaliplatin

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Organoplatinum Compounds
  • Oxaliplatin
  • Bevacizumab
  • Irinotecan
  • Cetuximab
  • Fluorouracil
  • Camptothecin